Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Influenza, Human 1Hemangiosarcoma 1Carcinoma, Squamous Cell 1

Interventions

Rituximab 15Cyclophosphamide 12fludarabine phosphate 11ibrutinib 10Bendamustine Hydrochloride 9fludarabine 7Peripheral Blood Stem Cell Transplantation 7Lenalidomide 6venetoclax 4Whole-Body Irradiation 4Radiotherapy 4idelalisib 3duvelisib 3acalabrutinib 3Mycophenolic Acid 3Methotrexate 3Melphalan 3In Situ Hybridization, Fluorescence 3Flow Cytometry 3Filgrastim 3Cytarabine 3Cyclosporine 3ofatumumab 2obinutuzumab 2Thiotepa 2Tacrolimus 2Pentetic Acid 2Etoposide 2Dexamethasone 2Dasatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Lymphocytic, Chronic, B-Cell × peginterferon alfa-2a × Clear all
NCT00962715 2012-08-03

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Influenza, Human, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡